Stock Code: 002294 Stock Abbreviation: Mindray Bio-Medical Announcement No.: 2026-034 Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Announcement on the Progress of the "Quality Return and Double Improvement" Action Plan
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and that there are no false records, misleading statements, or material omissions.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (hereinafter referred to as the "Company" or "Mindray Bio-Medical"), in order to implement the guiding principles of "invigorating the capital market, boosting investor confidence" and "vigorously enhancing the quality and investment value of listed companies, and taking more forceful and effective measures to stabilize the market and confidence," has made high-quality development its primary task. Based on local conditions, it has developed new quality productive forces, enhanced investor confidence, and protected the interests of all shareholders. In conjunction with its own development strategy, operating conditions, and financial situation, the Company has formulated the "Quality Return and Double Improvement" action plan. (For details, please refer to the "Announcement on the 'Quality Return and Double Improvement' Action Plan" published by the Company on the Juchao Information Network on August 31, 2024). The progress during the reporting period is hereby announced as follows:
In 2025, the Company actively implemented the "Quality Return and Double Improvement" action plan, focusing on its core business, continuously enhancing its core competitiveness and value creation capabilities. Through stable operating performance, active investor returns, and transparent and efficient information disclosure, it has built a bridge for benign communication with investors, actively responded to market concerns, and formed a virtuous cycle of improved operating quality and transmitted market value, continuously consolidating investors' confidence in the Company's long-term development and their recognition of its value.